ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2012
Leishmaniasis: new insights from an old and neglected disease.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Leishmaniasis and Trace Element Alterations: a Systematic Review.Biological trace element research · 2021Pooled it
- Next-generation sequencing of cell-free microbial DNA in blood samples of critically ill children: a single-center experience.Molecular and cellular pediatrics · 2026Article
- Whole-Genome Sequencing and Comparative Genomic Analysis ofMicroorganisms · 2026Article
- Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment.Biomedicines · 2025Review
- Occupational exposure to malaria, leishmaniasis and arbovirus vectors in endemic regions: A systematic review.Current research in parasitology & vector-borne diseases · 2024Review
- Antileishmanial evaluation of triazole-butenolide conjugates: design, synthesis,RSC medicinal chemistry · 2023Article
- Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host.Pathogens (Basel, Switzerland) · 2023Review
- Large scale systemic control short-circuits pathogen transmission by interrupting the sand rat (Psammomys obesus)-to-sand fly (Phlebotomus papatasi) Leishmania major transmission cycle.Medical and veterinary entomology · 2023Article
- Immunosuppressants alter the immune response associated with GlucantimeFrontiers in immunology · 2023Article
- Nanoparticles for Antimicrobial Agents Delivery-An Up-to-Date Review.International journal of molecular sciences · 2022Review
- Linear and conformational determinants of visceral leishmaniasis diagnostic antigens rK28 and rK39.Parasites & vectors · 2022Article
- Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.Frontiers in immunology · 2022Article
- Prognostic Value of Immunoglobulin G (IgG) Patterns by Western Blotting Immunodetection in Treated Dogs Previously Infected withVeterinary sciences · 2021Article
- Leishmaniasis: A new method for confirming cure and detecting asymptomatic infection in patients receiving immunosuppressive treatment for autoimmune disease.PLoS neglected tropical diseases · 2021Article
- Epidemiological and pathological characteristics of Cutaneous Leishmaniasis from Baluchistan Province of Pakistan.Parasitology · 2021Article
- Oviposition-Site Selection of Phlebotomus papatasi (Diptera: Psychodidae) Sand Flies: Attraction to Bacterial Isolates From an Attractive Rearing Medium.Journal of medical entomology · 2021Article
- Effect of immunosuppressants on the parasite load developed in, and immune response to, visceral leishmaniasis: A comparative study in a mouse model.PLoS neglected tropical diseases · 2021Article
- Antileishmanial Activity of Lignans, Neolignans, and Other Plant Phenols.Progress in the chemistry of organic natural products · 2021Article
- Investigation of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one as a promising coumarin compound for the development of a new and orally effective antileishmanial agent.Molecular biology reports · 2020Article
- Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?Microorganisms · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniases are a clinically heterogeneous group of diseases caused by protozoa of the genus Leishmania. There is growing evidence that the true incidence of the disease is underestimated, especially in hyperendemic regions. Moreover, climate changes together with the increasing movement of humans and animals raise concerns about the possible introduction of Leishmania infection in previously spared areas. The disease is emerging in immunocompromised patients undergoing bone marrow or solid organ transplantation or treatment with biologic drugs. Furthermore, the deployment of military troops and travel to endemic areas are associated with the observation of a growing number of patients with cutaneous disease. Improvement in diagnostic methods, both in the field and in specialized laboratories, has been obtained through the implementation of molecular amplification methods and using the rK39 antigen as the substrate. Finally, new therapeutic approaches are gaining attention, such as the use of miltefosine for cutaneous leishmaniasis and paromomycin for visceral leishmaniasis, as well as the use of various antileishmanial drugs in combination.
Indexed as
Identifiers
21533874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.